Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) reports corporate governance changes effective July 15, 2020. The report was filed on July 13, 2020, and pertains to the appointment of a new Chief Financial Officer and the reassignment of the interim CFO to the role of Chief Operating Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of CFO: Dennis Mulroy was appointed Chief Financial Officer, effective July 15, 2020.
- Resignation and Reassignment: Eric Loumeau resigned as interim CFO and was appointed Chief Operating Officer, effective July 15, 2020. He continues to serve as General Counsel.
- Compensation Structure:
- Dennis Mulroy: Annual base salary of $400,000; target cash bonus of up to 40% of base salary; granted an option to purchase 90,600 shares of common stock vesting over four years (25% at first anniversary, monthly thereafter).
- Eric Loumeau: Granted an option to purchase 10,000 shares of common stock vesting over four years (25% at first anniversary, monthly thereafter).
- Change in Control Provisions: Mr. Mulroy's agreement includes severance (12 months of salary and COBRA) and full vesting of options upon termination without cause or resignation for good reason within 13 months of a change in control, subject to a release. A "better after-tax" provision applies to parachute payments.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. No specific risks or contingencies are disclosed beyond standard employment agreement terms regarding termination and change in control.
Investor Verification Checklist
- Verify the effective date of the leadership transition (July 15, 2020).
- Review the specific vesting schedules for the 90,600 options granted to Mr. Mulroy and 10,000 options granted to Mr. Loumeau.
- Confirm the terms of the "change in control" severance package for the new CFO.
- Check the press release filed as Exhibit 99.01 for additional context on the leadership strategy.